Is actiq use in noncancer-related pain really "a recipe for success"? [1]

Pain Medicine

Volumn 9, Issue 2, 2008, Pages 258-260

  O'Connor, Alec B ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; FENTANYL CITRATE; MORPHINE; NARCOTIC ANALGESIC AGENT; OPIATE;

ANALGESIA; CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MISUSE; HIGH RISK PATIENT; HUMAN; LETTER; NARCOTIC DEPENDENCE; OFF LABEL DRUG USE; RISK REDUCTION;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANALGESICS, OPIOID; FEMALE; FENTANYL; HUMANS; PAIN; PREGNANCY; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 39649107318     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2008.00413.x     Document Type: Letter

References (16)

1. Passik SD, Kirsh KL. Weighing in on the off-label use of Actiq for noncancer-related pain: A recipe for success or a recipe for disaster. Pain Med 2007;8:130-3.
2. Hanks GW, de Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer 2001;84:587-93.
3. Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: A literature review. Eur J Pain 2007;11:490-518.
4. Zacny J, Bigelow G, Compton P, et al. College on problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: Position statement. Drug Alcohol Depend 2003;69:215-32.
5. Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain 2007;23:103-18.
6. Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: Opioid treatment for chronic back pain: Prevalence, efficacy, and association with addiction. Ann Intern Med 2007;146:116-27.
7. Lichtor JL, Sevarino FB, Joshi GP, et al. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg 1999;89:732-8.
8. Breivik H. Opioids in cancer and chronic non-cancer pain therapy-indications and controversies. Acta Anaesthesiol Scand 2001;45:1059-66.
9. Marsch LA, Bickel WK, Badger GJ, et al. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 2001;299:1056-65.
10. Coluzzi PH, Schwartzberg L, Conroy JD, Jr, et al. Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:123-30.
11. Fleming T. 2006 Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thompson Healthcare; 2006.
12. Taylor DR, Webster LR, Chun SY, et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: Patient perceptions and the effect of treatment with oral transmucosal fentanyl citrate (OTFC, Actiq). Pain Med 2007;8:281-8.
13. Porter ME, Teisberg EO. How physicians can change the future of health care. JAMA 2007;297:1103-11.
14. Bamezai A, Melnick G. Marginal cost of emergency department outpatient visits-an update using California Data. Med Care 2006;44:835-41.
15. US Department of Labor. Bureau of Labor Statistics. Consumer Price Indexes-Medical Care. Available at: ftp://ftp.bls.gov/pub/time.series/cu/ cu.data.15.USMedical. (accessed April 2007).
16. Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: The promotion of gabapentin: An analysis of internal industry documents. Ann Intern Med 2006;145:284-93.